Increases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen
- 3 November 2003
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 18 (1), 81-93
- https://doi.org/10.1096/fj.03-0038com
Abstract
A common phenotype in breast cancer is the expansion of the estrogen receptor-alpha (ER+) cell population and an inappropriate elevation of ERalpha protein, the latter predisposing patients for a poorer prognosis than those with lower levels of the receptor. A tetracycline-inducible ERalpha overexpression model was developed in the MCF-7 cell line to assess induction of endogenous gene activation and growth in response to elevations in ERalpha protein. Heightened levels of ERalpha resulted in aberrant promoter occupancy and gene activation in the absence of hormone, which was independent of ligand and AF-2 function. This increased receptor activity required the amino-terminal A/B domain and was not inhibited by tamoxifen, which supports an enhancement of AF-1 function, yet was independent of serine-104, 106, and 118 phosphorylation. Ligand-independent transcription was accompanied by an increase in growth in the absence of hormonal stimulation. The results suggest that elevated levels of ERalpha in breast cancer cells can result in activation of receptor transcriptional function in a manner distinct from classical mechanisms that involve ligand binding or growth factor-induced phosphorylation. Further, they describe a potential mechanism whereby increases in ERalpha concentration may provide a proliferative advantage by augmenting ERalpha function regardless of ligand status.Keywords
Funding Information
- National Cancer Institute (K01 CA-79090)
This publication has 55 references indexed in Scilit:
- Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growthProceedings of the National Academy of Sciences of the United States of America, 1998
- The Prognostic Significance of Steroid Receptor Activity in Tumor Tissues of Patients with Primary Breast CancerAmerican Journal of Clinical Oncology, 1997
- Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product?European Journal of Cancer, 1995
- Biological heterogeneity of er-positive breast cancers in the post-menopausal populationInternational Journal of Cancer, 1994
- Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancerEuropean Journal Of Cancer, 1993
- The limits of the cellular capacity to mediate an estrogen responseMolecular Endocrinology, 1992
- Pathophysiology of estrogen receptors in mammary tissue by monoclonal antibodiesJournal of Steroid Biochemistry, 1987
- Intracellular Receptor Concentration Limits Glucocorticoid-Dependent Enhancer Activity*Molecular Endocrinology, 1987
- Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancerBreast Cancer Research and Treatment, 1984
- Oestrogen receptors, cellularity, elastosis and menstrual status in human breast cancerEuropean Journal of Cancer (1965), 1978